Related references
Note: Only part of the references are listed.Regulator of G protein signaling-1 modulates paraquat-induced oxidative stress and longevity via the insulin like signaling pathway in Caenorhabditis elegans
Mingyu Wu et al.
TOXICOLOGY LETTERS (2017)
Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration
Shawn P. Alter et al.
EXPERIMENTAL NEUROLOGY (2016)
Fluorescent false neurotransmitter reveals functionally silent dopamine vesicle clusters in the striatum
Daniela B. Pereira et al.
NATURE NEUROSCIENCE (2016)
hVMAT2: A Target of Individualized Medication for Parkinson's Disease
Nian Xiong et al.
NEUROTHERAPEUTICS (2016)
Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals
Kelly M. Lohr et al.
TOXICOLOGICAL SCIENCES (2016)
Perfluorooctane sulfonate (PFOS) exposure could modify the dopaminergic system in several limbic brain regions
R. Salgado et al.
TOXICOLOGY LETTERS (2016)
Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity
Kelly M. Lohr et al.
ACS CHEMICAL NEUROSCIENCE (2015)
Visualization of neurotransmitter uptake and release in serotonergic neurons
Thorsten Lau et al.
JOURNAL OF NEUROSCIENCE METHODS (2015)
Selective damage to dopaminergic transporters following exposure to the brominated flame retardant, HBCDD
Kelly R. Genskow et al.
NEUROTOXICOLOGY AND TERATOLOGY (2015)
Environmental Toxins and Parkinson's Disease
Samuel M. Goldman
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 54 (2014)
Is Parkinson's Disease a Vesicular Dopamine Storage Disorder? Evidence from a Study in Isolated Synaptic Vesicles of Human and Nonhuman Primate Striatum
Christian Pifl et al.
JOURNAL OF NEUROSCIENCE (2014)
Drosophila modifier screens to identify novel neuropsychiatric drugs including aminergic agents for the possible treatment of Parkinson's disease and depression
H. O. Lawal et al.
MOLECULAR PSYCHIATRY (2014)
Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo
Kelly M. Lohr et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
New Fluorescent Substrate Enables Quantitative and High-Throughput Examination of Vesicular Monoamine Transporter 2 (VMAT2)
Gang Hu et al.
ACS CHEMICAL BIOLOGY (2013)
Vesicular Integrity in Parkinson's Disease
Shawn P. Alter et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2013)
Exposure to the polybrominated diphenyl ether mixture DE-71 damages the nigrostriatal dopamine system: Role of dopamine handling in neurotoxicity
Joshua M. Bradner et al.
EXPERIMENTAL NEUROLOGY (2013)
Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease
Laura Brighina et al.
NEUROBIOLOGY OF AGING (2013)
Gene-environment interactions in Parkinson's disease: Specific evidence in humans and mammalian models
Jason R. Cannon et al.
NEUROBIOLOGY OF DISEASE (2013)
Brain Dopamine-Serotonin Vesicular Transport Disease and Its Treatment
Jennifer J. Rilstone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Fluorescent dopamine tracer resolves individual dopaminergic synapses and their activity in the brain
Pamela C. Rodriguez et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport
Alison I. Bernstein et al.
JOURNAL OF NEUROSCIENCE METHODS (2012)
NEUROTOXIN-BASED MODELS OF PARKINSON'S DISEASE
J. Bove et al.
NEUROSCIENCE (2012)
Pesticide exposure and Parkinson's disease: Epidemiological evidence of association
Carmen Freire et al.
NEUROTOXICOLOGY (2012)
Rotenone, Paraquat, and Parkinson's Disease
Caroline M. Tanner et al.
ENVIRONMENTAL HEALTH PERSPECTIVES (2011)
PARAQUAT- AND ROTENONE-INDUCED MODELS OF PARKINSON'S DISEASE
R. Nistico et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2011)
VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease
Tonya N. Taylor et al.
PARKINSONS DISEASE (2011)
Vesicular monoamine transporter 2 mRNA levels are reduced in platelets from patients with Parkinson's disease
Gessica Sala et al.
JOURNAL OF NEURAL TRANSMISSION (2010)
The Drosophila vesicular monoamine transporter reduces pesticide-induced loss of dopaminergic neurons
Hakeem O. Lawal et al.
NEUROBIOLOGY OF DISEASE (2010)
Professional Exposure to Pesticides and Parkinson Disease
Alexis Elbaz et al.
ANNALS OF NEUROLOGY (2009)
Nonmotor Symptoms of Parkinson's Disease Revealed in an Animal Model with Reduced Monoamine Storage Capacity
Tonya N. Taylor et al.
JOURNAL OF NEUROSCIENCE (2009)
Protective Actions of the Vesicular Monoamine Transporter 2 (VMAT2) in Monoaminergic Neurons
Thomas S. Guillot et al.
MOLECULAR NEUROBIOLOGY (2009)
Fluorescent False Neurotransmitters Visualize Dopamine Release from Individual Presynaptic Terminals
Niko G. Gubernator et al.
SCIENCE (2009)
Dopamine Release at Individual Presynaptic Terminals Visualized with FFNs
Hui Zhang et al.
Jove-Journal of Visualized Experiments (2009)
Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis
Thomas S. Guillot et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice
Linan Chen et al.
JOURNAL OF NEUROSCIENCE (2008)
Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration
W. Michael Caudle et al.
JOURNAL OF NEUROSCIENCE (2007)
Divergent mechanisms of paraquat, MPP+, and rotenone toxicity: Oxidation of thioredoxin and caspase-3 activation
Sampath Ramachandiran et al.
TOXICOLOGICAL SCIENCES (2007)
Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease
Todd B. Sherer et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease
Jason R. Richardson et al.
FASEB JOURNAL (2006)
Pesticide exposure and risk for Parkinson's disease
Alberto Ascherio et al.
ANNALS OF NEUROLOGY (2006)
Polychlorinated biphenyl-induced reduction of dopamine transporter expression as a precursor to Parkinson's disease-associated dopamine toxicity
W. Michael Caudle et al.
TOXICOLOGICAL SCIENCES (2006)
Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women
CE Glatt et al.
HUMAN MOLECULAR GENETICS (2006)
Synaptophysin enhances the neuroprotection of VMAT2 in MPP+-induced toxicity in MN9D cells
CXQ Chen et al.
NEUROBIOLOGY OF DISEASE (2005)
PCB-induced inhibition of the vesicular monoamine transporter predicts reductions in synaptosomal dopamine content
JC Bemis et al.
TOXICOLOGICAL SCIENCES (2004)
Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: Role in neurodegenerative diseases
WJ Burke et al.
NEUROTOXICOLOGY (2004)
Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: Potential mouse model for parkinsonism
KA Mooslehner et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Share Paper
